| December 31, | September 30, | |||||||
2012 | 2013 | |||||||
| A s s e t s | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 2,873 | $ | 1,799 | ||||
| Restricted cash | 354 | 143 | ||||||
| Trade receivables | 3,869 | 2,629 | ||||||
| Inventory | 3,708 | 3,664 | ||||||
| Other receivable | 1,664 | 1,360 | ||||||
T o t a l current assets | 12,468 | 9,595 | ||||||
| LONG-TERM TRADE RECEIVABLES | 577 | 694 | ||||||
| SEVERANCE PAY FUND | 1,603 | 1,575 | ||||||
PROPERTY AND EQUIPMENT, net | 851 | 577 | ||||||
T o t a l assets | $ | 15,499 | 12,441 | |||||
| Liabilities and capital deficiency | ||||||||
| CURRENT LIABILITIES: | ||||||||
Trade payables | $ | 1,383 | $ | 1,509 | ||||
| Accrued expenses and other payables | 4,382 | 4,625 | ||||||
| Deferred income | 1,555 | 1,263 | ||||||
| Convertible subordinated notes, series A | 1,377 | 12,534 | ||||||
| Convertible subordinated notes, series B | 18 | 52 | ||||||
T o t a l current liabilities | 8,715 | 19,983 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Accrued severance pay and other | 1,956 | 1,892 | ||||||
| Deferred income | 717 | 810 | ||||||
| Convertible subordinated notes, series A | 11,588 | - | ||||||
| Convertible subordinated notes, series B | 510 | 947 | ||||||
| Long-term convertible loan from shareholders | 400 | 400 | ||||||
| T o t a l long-term liabilities | 15,171 | 4,049 | ||||||
T o t a l liabilities | 23,886 | 24,032 | ||||||
| CAPITAL DEFICIENCY | ||||||||
T o t a l capital deficiency | (8,387 | ) | (11,591 | ) | ||||
T o t a l liabilities and capital deficiency | $ | 15,499 | $ | 12,441 | ||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
| Revenues | $ | 1,638 | $ | 2,153 | $ | 6,308 | $ | 8,922 | ||||||||
| Cost of revenues | 630 | 575 | 2,181 | 3,542 | ||||||||||||
| Gross profit | 1,008 | 1,578 | 4,127 | 5,380 | ||||||||||||
| Research and development expenses - net | 605 | 1,498 | 1,808 | 4,770 | ||||||||||||
| Selling, General and administrative expenses | 964 | 2,063 | 3,408 | 7,451 | ||||||||||||
| Operating gain (loss) | (561 | ) | (1,983 | ) | (1,089 | ) | (6,841 | ) | ||||||||
| Financial income (expenses) - net | 423 | 1,630 | (2,501 | ) | 622 | |||||||||||
| Other income | - | - | 48 | - | ||||||||||||
| Net loss for the period | $ | (138 | ) | $ | (353 | ) | $ | (3,542 | ) | $ | (6,219 | ) | ||||
| Loss per share ("EPS"): | ||||||||||||||||
Basic | $ | (0.00 | ) | $ | (0.01 | ) | $ | (0.11 | ) | $ | (0.25 | ) | ||||
Diluted | $ | (0.03 | ) | $ | (0.03 | ) | $ | (0.11 | ) | $ | (0.25 | ) | ||||
| Weighted average number of shares used in | ||||||||||||||||
computation of EPS (in thousands): | ||||||||||||||||
| Basic | 31,073 | 29,216 | 31,057 | 24,933 | ||||||||||||
| Diluted | 33,197 | 34,635 | 31,057 | 26,131 | ||||||||||||
| Interim condensed consolidation statement of comprehensive loss: | ||||||||||||||||
| Net loss for the period | $ | (138 | ) | $ | (353 | ) | $ | (3,542 | ) | $ | (6,219 | ) | ||||
| Other comprehensive income: | ||||||||||||||||
| Gain on available-for-sale marketable securities | - | (1,156 | ) | - | (133 | ) | ||||||||||
| Net comprehensive loss for the period | $ | (138 | ) | $ | (1,509 | ) | $ | (3,542 | ) | $ | (6,352 | ) | ||||
